Where Is Visceral Fat Located in the Body?

Visceral fat is located deep within the abdominal cavity, packed around vital organs including the liver, pancreas, intestines and kidneys. Unlike subcutaneous fat, which sits just beneath the skin and can be pinched, visceral fat is entirely hidden from view and cannot be felt from the outside. Its position within the body is not merely anatomical detail: where visceral fat is stored directly determines how it behaves metabolically and why excess accumulation is linked to serious health conditions including type 2 diabetes, cardiovascular disease and fatty liver disease. Understanding its location is the first step towards assessing and managing your risk.

Where exactly is visceral fat stored in the body?

Visceral fat is stored deep within the abdominal cavity, primarily in the omentum and mesentery, surrounding organs including the liver, pancreas, intestines and kidneys. It cannot be seen or felt from outside the body.

Visceral fat is stored deep within the abdominal cavity, packed around the internal organs including the liver, pancreas, intestines and kidneys. Unlike fat that sits just beneath the skin, visceral fat occupies the spaces between and around these vital structures. The largest intra-abdominal depot is held within a large fold of tissue called the omentum, which drapes from the stomach and large intestine (omental fat). A further deposit, known as mesenteric fat, surrounds the blood vessels supplying the gut. Together, these omental and mesenteric stores make up the clinically relevant visceral fat compartment.

Because visceral fat lies so far beneath the surface, it cannot be seen or felt directly. A person may appear relatively slim on the outside while still carrying a clinically significant amount of visceral fat internally. This pattern is sometimes described as metabolically unhealthy normal weight (MONW) and is one reason why body weight alone is a poor indicator of metabolic health. MONW is a descriptive term used in research rather than a formal clinical diagnosis.

Smaller deposits of ectopic fat also accumulate around the heart (epicardial and pericardial fat) and around the kidneys (perirenal fat), and these are sometimes grouped under the broader term ectopic adipose tissue. However, the largest and most clinically relevant depot remains the intra-abdominal store surrounding the digestive organs. Understanding where visceral fat sits helps explain why it behaves so differently from other fat in the body, and why its accumulation carries particular health implications that go well beyond appearance.

How is visceral fat different from subcutaneous fat?

Visceral fat lies deep inside the abdominal cavity and is far more metabolically active than subcutaneous fat, releasing higher levels of inflammatory cytokines and draining directly into the portal vein, which drives insulin resistance and cardiovascular risk.

Visceral fat and subcutaneous fat differ fundamentally in their location, structure and metabolic behaviour. Subcutaneous fat sits directly beneath the skin, across areas such as the thighs, buttocks, upper arms and abdomen, and can be pinched between the fingers. Visceral fat, by contrast, lies deep inside the abdominal cavity, beyond the abdominal muscles, and is entirely inaccessible from the outside.

The two fat types also behave differently at a cellular and hormonal level. Visceral fat is more metabolically active than subcutaneous fat, meaning it releases fatty acids, inflammatory proteins and hormones at a higher rate. In particular, the omental and mesenteric depots drain directly into the portal vein, which carries blood straight to the liver. This portal drainage pathway means the liver is exposed to a high concentration of free fatty acids and inflammatory signals, contributing to insulin resistance and raised triglyceride levels. Other ectopic fat depots (such as epicardial fat) drain via the systemic circulation rather than the portal vein, but still contribute to local and systemic inflammation.

Visceral fat also produces higher levels of pro-inflammatory cytokines, including interleukin-6 and tumour necrosis factor-alpha, and lower levels of adiponectin, a hormone that helps regulate glucose and has anti-inflammatory properties. Subcutaneous fat, while not entirely benign in excess, is generally considered less harmful metabolically. Research consistently shows that the distribution of fat, not just the total amount, is a key determinant of cardiometabolic risk. This distinction matters clinically because two people with the same body mass index (BMI) can have very different health profiles depending on where their fat is stored.

Can you tell if you have too much visceral fat without a scan?

Waist circumference is the most practical clinical proxy: UK thresholds for increased risk are above 94 cm in men and above 80 cm in women, with lower cut-offs for South Asian and other ethnic groups. Accurate quantification requires CT, MRI or DEXA imaging.

Waist circumference is the most practical and widely used clinical proxy for estimating visceral fat without imaging. NICE guidance on obesity and cardiovascular risk recommends measuring waist circumference as part of routine assessment, particularly in people with a BMI below 35 kg per square metre, where it adds meaningful information about metabolic risk.^[7][8]

In the UK, thresholds associated with increased health risk are a waist circumference above 94 cm (37 inches) in men and above 80 cm (31.5 inches) in women, with substantially increased risk above 102 cm in men and 88 cm in women. These thresholds are derived from WHO and International Diabetes Federation (IDF) criteria and are widely used in UK clinical practice. Importantly, these thresholds are not universal: lower cut-offs apply to people of South Asian, Chinese and Japanese descent, among other ethnic groups, because central adiposity confers greater metabolic risk at a lower waist circumference in these populations. If you are from a South Asian background, for example, a waist above 90 cm in men or 80 cm in women is considered a marker of increased risk. Your GP can advise on which thresholds are most relevant to you.

To measure your waist correctly, stand relaxed and breathe out gently. Place the tape measure midway between the bottom of your lowest rib and the top of your hip bone (roughly at the level of your navel), keeping it horizontal and snug but not tight.

Waist-to-height ratio is also used in research and clinical settings. A simple rule of thumb is to keep your waist measurement to less than half your height; a ratio above 0.5 is considered a marker of central adiposity across most adult populations. These measurements are imperfect, however, because they capture overall abdominal girth rather than distinguishing precisely between visceral and subcutaneous fat.

For a more accurate assessment, imaging is required. Computed tomography (CT) scanning and magnetic resonance imaging (MRI) can quantify visceral fat volume directly, but these are not used routinely in clinical practice due to cost and, in the case of CT, radiation exposure.^[13] Dual-energy X-ray absorptiometry (DEXA) scanning offers a reasonable estimate of fat distribution and is available in some specialist weight management and research settings, though it is not routinely commissioned by Integrated Care Boards (ICBs) for obesity assessment.^[20] Bioelectrical impedance devices, including some consumer-grade scales, claim to estimate visceral fat, but their accuracy varies considerably and results should not guide clinical decisions without professional assessment. If you are concerned about your risk, speaking to your GP is the appropriate first step.

Why does visceral fat around your organs matter for health?

Excess visceral fat is independently associated with type 2 diabetes, cardiovascular disease, MASLD and metabolic syndrome, because it releases fatty acids and inflammatory cytokines into the portal circulation, promoting insulin resistance and accelerating atherosclerosis.

Excess visceral fat is independently associated with an increased risk of type 2 diabetes, cardiovascular disease, fatty liver disease, certain cancers and metabolic syndrome, making it one of the most clinically significant modifiable risk factors in adult health.^[3][2] The mechanisms are well established: visceral fat releases free fatty acids and inflammatory cytokines into the portal circulation, promoting insulin resistance in the liver, raising blood glucose and triglycerides, and lowering HDL ("good") cholesterol. Over time, these changes accelerate atherosclerosis and are associated with increased risk of heart attack and stroke.

The liver is particularly vulnerable. When exposed to a sustained excess of fatty acids from visceral fat, liver cells begin to accumulate fat themselves, a condition known as metabolic dysfunction-associated steatotic liver disease (MASLD), previously called non-alcoholic fatty liver disease (NAFLD). Both terms remain in use: NHS patient resources currently use NAFLD, while UK and European specialist guidelines are progressively adopting MASLD.^[15][16] Left unaddressed, this can progress to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and, in some cases, cirrhosis. NICE guidance (NG49) and NHS England have both highlighted this condition as a growing public health concern closely linked to central obesity.^[14][15]

Visceral fat is also associated with chronic low-grade inflammation throughout the body, which is implicated in conditions including polycystic ovary syndrome (PCOS), obstructive sleep apnoea and certain hormone-sensitive cancers. The word "associated" is used deliberately: while the links are well supported by research, the direction of causality is not always straightforward.

Importantly, visceral fat responds well to lifestyle intervention. Evidence suggests that a modest reduction in body weight of around 5 to 10 per cent, achieved through regular aerobic exercise and a calorie-appropriate diet, can meaningfully reduce visceral fat and improve metabolic markers, often before significant changes in overall body weight are apparent.^[19] Where clinically indicated, pharmacological support may also be considered.

If you are concerned about your metabolic health, your GP can assess your risk and discuss appropriate next steps, including referral to a specialist weight management service where relevant. Access to such services depends on local ICB commissioning and eligibility criteria.

Frequently Asked Questions